SCYNEXIS to Participate in Antifungals Panel at Maxim Group’s Infectious Disease Virtual Conference
The Renaissance of the Anti-infective Sector - Seite 2
About Maxim’s Infectious Disease Virtual Conference
The Infectious Disease Virtual Conference is being presented by Maxim Group, LLC (Maxim). There will be four panels of
companies in various stages of development, from early stage to near commercialization, that represent the next wave of innovation in the healthcare industry. Please contact Soraya Dorce
(sdorce@maximgrp.com) or visit M-Vest for more information and to register for the conference.
About Ibrexafungerp
Ibrexafungerp [pronounced eye-BREX-ah-FUN-jerp] is an investigational antifungal agent and the first representative of a novel class of structurally-distinct glucan synthase inhibitors,
triterpenoids. This agent combines the well-established activity of glucan synthase inhibitors with the potential flexibility of having oral and intravenous (IV) formulations. Ibrexafungerp is
currently in development for the treatment of fungal infections caused primarily by Candida (including C. auris) and Aspergillus species. It has
demonstrated broad-spectrum antifungal activity, in vitro and in vivo, against multidrug-resistant pathogens, including azole- and
echinocandin-resistant strains. The FDA has granted Qualified Infectious Disease Product (QIDP) and Fast Track designations for the formulations of ibrexafungerp for the indications of invasive
candidiasis (IC) (including candidemia), invasive aspergillosis (IA) and VVC, and has granted Orphan Drug Designation for the IC and IA indications. Ibrexafungerp is formerly known as SCY-078.
Lesen Sie auch
About SCYNEXIS
SCYNEXIS, Inc. (NASDAQ: SCYX) is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by
developing innovative therapies. The SCYNEXIS team has extensive experience in the life sciences industry, having discovered and developed more than 30 innovative medicines
over a broad range of therapeutic areas. SCYNEXIS's lead product candidate, ibrexafungerp (formerly known as SCY-078), is a novel IV/oral antifungal agent in Phase 3 clinical and preclinical
development for the treatment of multiple serious and life-threatening invasive fungal infections caused by Candida and Aspergillus species. For more
information, visit www.scynexis.com.